Navigation Links
Biopharmaceutical Industry Veterans Join Inspiration Biopharmaceuticals Board of Directors
Date:9/18/2012

CAMBRIDGE, Mass., Sept. 18, 2012 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. (Inspiration) announced today the appointment of two new independent Directors to the Company's Board of Directors. Scott A. Canute and Gino Santini provide Inspiration access to unparalleled expertise in biopharmaceuticals manufacturing and business development as the company moves toward commercialization of its portfolio of products currently in late-stage development for hemophilia. The new independent Directors were appointed by specialty pharmaceutical company Ipsen, who holds rights to commercialize Inspiration's two late-stage hemophilia product candidates in Europe and certain other territories. Ipsen gained the right to designate two new members to Inspiration's board under the terms of agreements announced by the companies on August 21, 2012.

"We are pleased to have our Board enhanced by these talented executives," said John Taylor, Co-Founder and Chairman of the Board of Inspiration. "They deeply understand Inspiration's mission to broaden treatment choices, expand global access to care and advance innovative therapies for the hemophilia community. Each brings a unique set of experiences that will be instrumental to Inspiration as we continue to develop as an independent company and work to create new products to help people with hemophilia."

Scott A. Canute has over 30 years of experience in the biopharmaceutical industry. He has most recently served as the President of Global Manufacturing and Corporate Operations and Executive Vice President of Genzyme Corporation from March 2010 to July 2011, leading a major turnaround effort for the manufacturing division of the global biotechnology company. Prior to that, Mr. Canute spent 25 years at Eli Lilly and Company in a variety of positions culminating in his becoming President of Manufacturing in 2004. Mr. Canute is currently a board member of Oncobiologics, Inc. and has been a past board member of the Indiana Manufacturers Association and the National Association of Manufacturers. Mr. Canute holds a Bachelor of Science Degree in Chemical Engineering from the University of Michigan and a Master of Business Administration from the Harvard Business School.

Gino Santini is a senior advisor for venture capital, pharmaceutical and biotechnology companies. He is currently a board member of AMAG Pharmaceuticals, Horizon Pharma, SORIN SpA, Allena Pharmaceuticals and Collegium Pharmaceuticals. He retired from Eli Lilly and Company in 2011 as Senior Vice President of Corporate Strategy and Business Development after 27 years with the company, where he had been a member of the Executive Committee since 2004. From 1999 to 2004, he was President of U.S. Operations. Mr. Santini is a past Chairman of the Board of the National Pharmaceutical Council. He also served on the Board of Directors of the United Way and the Executive Committee and Board of the Indianapolis Chamber of Commerce. Mr. Santini holds a degree in mechanical engineering from the University of Bologna and a Master of Business Administration from the Simon School of Business, University of Rochester.

"These new appointments to our Board of Directors bring critical expertise to Inspiration," said John P. Butler, Chief Executive Officer. "Scott and Gino have vast experience in areas that are vital to us as a growing biopharmaceutical company on the verge of commercialization. Scott's manufacturing expertise is unparalleled in the industry. Gino has decades of experience in the development and negotiation of strategic partnerships and alliances, which will help Inspiration choose the best path as we move forward. With these additions, Inspiration's Board of Directors is ideally suited to help us develop innovative treatment options that meet the needs of the global hemophilia community."

More information about Inspiration's Board of Directors is available on the Board of Directors page at www.inspirationbio.com.

About Inspiration BiopharmaceuticalsAs the only biopharmaceutical company dedicated solely to hemophilia, Inspiration is committed to improving the care of people with this condition by broadening treatment choices, expanding global access to care and advancing innovative therapies. Founded by two families whose sons have hemophilia, Inspiration is inspired to make a difference in the lives of people impacted by hemophilia around the world. Inspiration's lead product candidates are IB1001, an investigational intravenous recombinant factor IX being developed for the treatment of hemophilia B, and OBI-1, an investigational recombinant porcine factor VIII being developed for the treatment of serious bleeds in patients with congenital hemophilia A with inhibitors or acquired hemophilia A.

For more information about Inspiration Biopharmaceuticals, please visit www.inspirationbio.com.Contacts:Media  InvestorsKate LewisGordon H. BusenbarkFeinstein Kean HealthcareSenior Vice President, Chief Financial OfficerTel: +1-617-577-8Tel: +1-617-588-1802Email: kate.lewis@fkhealth.com  


'/>"/>
SOURCE Inspiration Biopharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
2. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
3. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
4. New Study Details Foreign Efforts To Lure Biopharmaceutical Companies
5. Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
6. Inspiration Biopharmaceuticals Reports Positive Interim Results from the Accur8 Phase 2/3 Study of OBI-1 in Acquired Hemophilia A at WFH 2012 World Congress
7. Inspiration Biopharmaceuticals Announces Clinical Hold of Clinical Trials Evaluating IB1001 for the Treatment and Prevention of Bleeding in Hemophilia B
8. PAREXEL Launches The PAREXEL BioPharm Unit To Meet The Critical Development Goals Of Small And Mid-Sized Biopharmaceutical Companies
9. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Second Quarter 2012 Financial Results
10. Biopharmaceutical Service Providers Announce Collaborative Opening of Boston, MA Office
11. The Thousand-Year Business Model for a Modern Biopharmaceutical Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... YORK , December 2, 2016 ... Braces & Support) is Expected to Gain a Significant Market ... to Orthopedic Ailments  ... , According to ... Study on Medical Implants Sterile Packaging: Clamshell Product Type Segment ...
(Date:12/2/2016)... On Thursday, the NASDAQ Composite and ... the Dow Jones Industrial Average managed to stay in green. ... which prompted Stock-callers this morning to look at the performances ... NUVA ), Smith & Nephew PLC (NYSE: SNN ... Cesca Therapeutics Inc. (NASDAQ: KOOL ). You can ...
(Date:12/2/2016)... -- The concept of rare diseases and the idea that ... has been taking shape in Europe ... initiatives related to orphan medicinal products have been emerging at ... states individually. Many member states in the EU have led ... medicinal products, the result of which took the shape of ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... The annual time frame to change Medicare health ... is ending December 7th. Currently-enrolled Medicare beneficiaries who are looking to switch from their ... D) need to make changes during this period order for their new policy to ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... More than ... and while 84 percent of parents report speaking with their child about sex related ... sexually transmitted diseases. , Mediaplanet is proud to announce the launch of its second ...
(Date:12/2/2016)... ... December 02, 2016 , ... Sourced from the Isbre Springs beneath the 5,000 ... unmatched natural purity of just 6 ppm TDS (Total Dissolved Solids) in addition to ... been available in several ShopRite and FoodTown stores in NJ and received rave comments ...
(Date:12/2/2016)... Miami, FL (PRWEB) , ... December 02, 2016 ... ... over 5,100 hot meals to needy individuals and families from eight different sites ... Florida on Thanksgiving Day. Over 1,000 volunteers worked very hard on Thanksgiving morning ...
(Date:11/30/2016)... , ... November 30, 2016 , ... ... they now offer a comprehensive in-house dental plan for all patients. Understanding that ... a plan that gives patients a number of perks, including discounts on many ...
Breaking Medicine News(10 mins):